Metabolic changes during medical treatment of endometriosis: Nafarelin acetate versus danazol

Kenneth A. Burry, Phillip E. Patton, D. Roger Illingworth

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


In this double-blind study of changes in plasma lipid and lipoprotein concentrations during 6-month medical treatment of endometriosis, 53 patients were randomly assigned to one of four treatment schedules: danazol, 800 mg/day (n = 10); danazol, 600 mg/day (n = 8); intranasal nafarelin acetate, 800 μg/day (n = 10); or intranasal nafarelin acetate, 400 μg/day (n = 25). Plasma levels of triglycerides, cholesterol, and low-density lipoprotein, very low-density lipoprotein, and high-density lipoprotein cholesterol fractions were obtained before,'during, and 1 month after treatment. High-density lipoprotein, and high-density lipoprotein3, cholesterol concentrations were measured in selected patients. Body weight was also followed. The drugs were equally effective in achieving symptomatic relief and laparoscopically demonstrated resolution of endometriosis but differed significantly in their effects on lipid concentrations. Nafarelin acetate had no adverse effects on serum lipoprotein concentrations, whereas danazol significantly decreased high-density lipoprotein cholesterol (p < 0.01), as well as the high-density lipoprotein2 subtraction (p < 0.05), and increased low-density lipoprotein cholesterol (p < 0.01). Danazol significantly increased body weight (p < 0.01), whereas nafarelin did not.

Original languageEnglish (US)
Pages (from-to)1454-1461
Number of pages8
JournalAmerican journal of obstetrics and gynecology
Issue number6
StatePublished - Jun 1989


  • Danazol
  • cholesterol
  • endometriosis
  • lipoproteins
  • nafarelin acetate

ASJC Scopus subject areas

  • Obstetrics and Gynecology


Dive into the research topics of 'Metabolic changes during medical treatment of endometriosis: Nafarelin acetate versus danazol'. Together they form a unique fingerprint.

Cite this